Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Selected adipocytokines and their potential role in the control of the course
of chronic hepatitis B and C
| 1 | Oddział Chorób Wewnętrznych II, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku |
| 2 | Oddział Endokrynologii i Diabetologii, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku |
| 3 | Zakład Patofizjologii Katedry Patofizjologii i Endokrynologii
Wydziału Lekarskiego z Oddziałem Lekarsko-Dentystycznym w Zabrzu Śląskiego Uniwersytetu Medycznego w Katowicach |
CORRESPONDING AUTHOR
Joanna Olszok
Oddział Chorób Wewnętrznych II, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku, ul. Energetyków 46, 42-200 Rybnik, tel. 32 429 12 51
Oddział Chorób Wewnętrznych II, Wojewódzki Szpital Specjalistyczny nr 3 w Rybniku, ul. Energetyków 46, 42-200 Rybnik, tel. 32 429 12 51
Ann. Acad. Med. Siles. 2015;69:1–7
KEYWORDS
liveradipokinesChronic Hepatitis Bchronic hepatitis Cfibrosissteatosisadiponectinleptinresitinvisfatin
TOPICS
ABSTRACT
Chronic hepatitis B and C are among the most common liver diseases. A prolonged necroinflammatory process may lead to life-threatening complications although in some cases the liver condition remains stable for many years. Due to its unpredictable prognosis, a great deal of research has been carried out to find additional factors that modify the course of these diseases. Adipocytokines, substances secreted mainly by adipose tissue cells, have become the object of various studies due to their pluripotent impact. This paper aims to present the interrelationship of selected adipocytokines and hepatitis B and C, as well as the potential use of this knowledge in medical practice.
REFERENCES (74)
1.
Tuchacz S., Gruchała M., Karbowska J., Kochan Z., Sobiczewski W., Rynkiewicz A. Adiponektyna w chorobie wieńcowej – przegląd piśmiennictwa. Pol. Prz. Kardiol. 2007; 9: 215–219.
2.
Niemczyk S., Romejko-Ciepielewska K., Niemczyk L. Zaburzenia funkcji hormonalnej tkanki tłuszczowej i w zakresie hormonów płciowych u chorych z przewlekłą niewydolnością nerek. Endokrynol. Pol. 2012; 63: 148–155.
3.
Olszanecka-Glinianowicz M., Handzlik-Orlik G., Orlik B., Chudek J. Rola adipokin w patogenezie nieswoistych zapaleń jelita grubego. Endokrynol. Pol. 2013; 64: 226–231.
4.
Rystwej-Niedźwiedzka P., Deptuła W. Tkanka tłuszczowa a układ odpornościowy. Alergia Astma Immunol. 2009; 15: 101–105.
5.
Pluskiewicz W., Adamczyk P., Marek B. i wsp. Adiponektyna i rezystyna a stan szkieletu u kobiet uczestniczących w badaniu RAC-OST-POL. Endokrynol. Pol. 2012; 63: 427–431.
6.
Gałecka-Wanatowicz D., Chomyszyn-Gajewska M. Otyłość a stan tkanek przyzębia – przegląd piśmiennictwa. Czas. Stomat. 2009; 62: 649–656.
7.
Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957–969.
8.
Pajvani U.B., Du X., Combs T.P. i wsp. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem. 2003; 278: 9073–9085.
9.
Weyer C., Funahashi T., Tanaka S. i wsp. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001; 86: 1930–1935.
10.
Miyazaki T., Shimada K., Mokuno H., Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart 2003; 89: 663.
11.
Shimada K., Miyazaki T., Daida H. Adiponectin and atherosclerotic disease. Clin. Chim. Acta 2004; 344: 1–12.
12.
Tacke F., Wüstefeld T., Horn R. i wsp. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 2005; 42: 666–673.
13.
Tsochatzis E., Papatheodoridis G.V., Hadziyannis E. i wp. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand. J. Gastroenterol. 2008; 43: 1128–1136.
14.
Siagris D., Vafiadis G., Michalaki M. i wsp. Serum adiponectin in chronic hepatitis C and B. J. Viral. Hepat. 2007; 14: 577–583.
15.
Liu C.J., Chen P.J., Lai M.Y. i wsp. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol. Int. 2009; 3: 364–370.
16.
Hui C.K., Zhang H.Y., Lee N.P. i wsp. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J. Hepatol. 2007; 47: 191–202.
17.
Wong V.W., Wong G.L., Yu J. i wsp. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am. J. Gastroenterol. 2010; 105: 132–138.
18.
Lu J.Y., Su T.C., Liu Y.H., Hsu H.J., Chen C.L., Yang W.S. Lower plasma adiponectin is correlated to higher alanine aminotransferase independent of metabolic factors and hepatitis B virus carrier status. Intern. Med. J. 2007; 37: 365–371.
19.
Korah T.E., El-Sayed S., Elshafie M.K., Hammoda G.E., Safan M.A. Signifi-cance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J. Hepatol. 2013; 5: 74–81.
20.
Jonsson J.R., Moschen A.R., Hickman I.J. i wsp. Adiponectin and its recep-tors in patients with chronic hepatitis C. J. Hepatol. 2005, 436: 929–936.
21.
Costantini S., Capone F., Guerriero E. i wsp. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One 2012; 7: e39486.
22.
Petit J.M., Minello A., Jooste V. i wsp. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J. Clin. Endocrinol. Metab. 2005; 90: 2240–2243.
23.
Liu C.J., Chen P.J., Jeng Y.M. i wsp. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J. Hepatol. 2005; 43: 235–242.
24.
Ashour E., Samy N., Sayed M., Imam A. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. Clin. Lab. 2010; 56: 103–110.
25.
Wang A.Y., Hickman I.J., Richards A.A., Whitehead J.P., Prins J.B., Macdonald G.A. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am. J. Gastroenterol. 2005; 100: 2717–2723.
26.
Zografos T.A., Liaskos C., Rigopoulou E.I. i wsp. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am. J. Gastroenterol. 2008; 103: 605–614.
27.
Kara B., Gunesacar R., Doran F., Kara I.O., Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv. Ther. 2007; 24: 972–982.
28.
Meng Q.H., Duan Z.H., Lin Z.H., Yu H.W., Li J., Liu Y. Serum level of adiponectin correlated with gender and genotype in patients with chronic hepatitis C. Dig. Dis. Sci. 2009; 54: 1120–1127.
29.
Latif H.A., Assal H.S., Mahmoud M., Rasheed W.I. Role of serum adiponec-tin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin. Exp. Med. 2011; 11: 123–129.
30.
Fukushima N., Kuromatsu R., Arinaga-Hino T. i wsp. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol. Res. 2010; 40: 911–922.
31.
Palmer C., Hampartzoumian T., Lloyd A., Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008; 48: 374–384.
32.
Lu J.Y., Chuang L.M., Yang W.S. i wsp. Adiponectin levels among patients with chronic hepatitis B and C infections and in response.
34.
Khattab M.A., Eslam M., Shatat M. i wsp. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J. Gastrointestin. Liver Dis. 2012; 21: 59–65.
35.
Saad Y., Ahmed A., Saleh D.A., Doss W. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur. J. Gastroenterol. Hepatol. 2013; 25: 920–925.
36.
Matkovic V., Ilich J.Z., Badenhop N.E. i wsp. Gain in body fat is inversely related to the nocturnal rise in serum leptin level in young females. J. Clin. Endocrinol. Metab. 1997; 82: 1368–1372.
37.
Tungtrongchitr R., Treeprasertsuk S., Ei N.N., Thepouyporn A., Phonrat B., Huntrup A. Serum leptin concentrations in chronic hepatitis. J. Med. Assoc. Thai. 2006; 89: 490–499.
38.
Testa R., Franceschini R., Giannini E. i wsp. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J. Hepatol. 2000; 33: 33–37.
39.
Żwirska-Korczala K., Kukla M., Ziółkowski A. i wsp. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp. Clin. Hep. 2005; 1: OR60-5.
40.
Giannini E., Ceppa P., Botta F. i wsp. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am. J. Gastroenterol. 2000; 95: 3211–3217.
41.
Baranova A., Jarrar M.H., Stepanova M. i wsp. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion 2011; 83: 32–40.
42.
Piche T., Vandenbos F., Abakar-Mahamat A. i wsp. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J. Viral. Hepat. 2004; 11: 91–96.
43.
Kukla M., Żwirska-Korczala K., Gabriel A. i wsp. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J. Viral. Hepat. 2010; 17: 661–667.
44.
Bolukbas F.F., Bolukbas C., Horoz M. i wsp. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterol. 2004; 4: 23.
45.
El-Gindy E.M., Ali-Eldin F.A., Meguid M.A. Serum leptin level and its association with fatigue in patients with chronic hepatitis C virus infection. Arab. J. Gastroenterol. 2012; 13: 54–57.
46.
Gordon A., McLean C.A., Pedersen J.S., Bailey M.J., Roberts S.K. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J. Hepatol. 2005; 43: 38–44.
47.
Myers R.P., Messous D., Poynard T., Imbert-Bismut F. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can. J. Gastroenterol. 2007; 21: 289–294.
48.
Zografos T.A., Rigopoulou E.I., Liaskos C. i wsp. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J. Hepatol. 2006; 44: 848–855.
49.
Eguchi Y., Mizuta T., Yasutake T. i wsp. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J. Gastroenterol. 2006; 12: 556–560.
50.
Manolakopoulos S., Bethanis S., Liapi C. i wsp. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol. 2007; 7: 17.
51.
Steppan C.M., Brown E.J., Wright C.M. i wsp. A family of tissue−specific resistin−like molecules. Proc. Natl. Acad. Sci. U S A 2001; 98: 502–506.
52.
Pang S.S., Le Y.Y. Role of resistin in inflammation and inflammation-related diseases. Cell. Mol. Immunol. 2006; 3: 29–34.
53.
Wang H., Chu W., Hemphill C., Elbein S. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J. Clin. Endocr. Metab. 2002; 87: 2520–2524.
54.
Karbowska A., Boratyńska M., Klinger M. Rezystyna – czynnik patogenetyczny czy biomarker zaburzeń metabolicznych i zapalenia? Postepy Hig. Med. Dosw. 2009; 63: 485–491.
55.
Morace C., Spadaro A., Cucunato M. i wsp. High serum resistin in chronic viral hepatitis is not a marker of metabolic disorder. Hepatogastroenterology 2010; 57: 1215–1219.
56.
Durazzo M., Belci P., Niro G. i wsp. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. J. Endocrinol. Invest. 2013; 36: 600–605.
57.
Zhang L.Q., Heruth D.P., Ye S.Q. Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 2011; 3: 13–25.
58.
Cybulska B. Komentarz redakcyjny: Wisfatyna – co dotychczas wiadomo o jej roli w fizjologii i patologii? Kardiol. Pol. 2011; 69: 808–809.
59.
Benedict C., Shostak A., Lange T. i wsp. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism. J. Clin. Endocrinol. Metab. 2012; 97: E218–222.
60.
Fukuhara A., Matsuda M., Nishizawa M. i wsp. Visfatin: a protein secrated by visceral fat that mimics the effects of insulin. Science 2005; 21: 426–430.
61.
Berndt J., Kloting N., Kralisch S. i wsp. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54; 2911–2916.
62.
Rubbia-Brandt L., Fabris P., Paganin S. i wsp. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406–412.
63.
Kukla M., Żwirska-Korczala K., Gabriel A. i wsp. Visfatin serum levels in chronic hepatitis C patients. J. Viral. Hepat. 2010; 17: 254–260.
64.
Moschen A.R., Kaser A., Enrich B. i wsp. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007; 178: 1748–1758.
65.
Hano A.E., Deghady A., Shaaban S., Rahman M. Serum Visfatin in patients with chronic hepatitis C. Am. J. Sci. 2011; 7: 94–101.
66.
Chen L., Liu W., Lai S., Li Y., Wang X., Zhang H. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients. Eur. J. Gastroenterol. Hepatol. 2013; 25: 935–941.
67.
Huang J.F., Huang C.F., Yu M.L. i wsp. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 2011; 26: 530–535.
68.
Kukla M., Mazur W., Bułdak R.J., Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol. Med. 2011; 17: 1397–1410.
69.
Kukla M., Waluga M., Sawczyn T. i wsp. Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy. Pol. J. Pathol. 2012; 63: 213–220.
70.
Principe A., Melgar-Lesmes P., Fernández-Varo G. i wsp. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008; 48: 1193–1201.
71.
El-Mesallamy H.O., Hamdy N.M., Rizk H.H., El-Zayadi A.R. Apelin serum level in Egyptian patients with chronic hepatitis C. Mediators Inflamm. 2011; 2011: 703031.
72.
Tonelli J., Li W., Kishore P. i wsp. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53: 1621-9. Erratum in: Diabetes 2005; 54: 587.
73.
Furuhashi M., Ura N., Takizawa H. i wsp. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 2004; 22: 1977–1982.
74.
Shimada K., Kawarabayashi T., Tanaka A. Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. Diabetes Res. Clin. Pract. 2004; 65: 227–234.
RELATED ARTICLE
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.